Radar›Companies›Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 6
United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 6

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderDelcath · 54
Strongest available pathIRadimed · +157.7%
Widest latest marginIRadimed · 26.8%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DCTH · Nasdaq

Delcath

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1987New York City, New York$567.0M market cap
View full Companies Radar profile
54Moderate
Snapshot price$16.34as of page date
Monthly-close return+63.9%five-year window
FY2025 revenue$0.09BDELCATH SYSTEMS, INC.
Net margin3.2%FY2025
P/E snapshot1634.0xone ratio, not a verdict
Prism attention27.9%share across these five
Filing track recordRevenue, USD billions
+2297.5%
$0$0.0B$0.1B$0.1BFY2021: $0.004BFY2022: $0.003BFY2023: $0.002BFY2024: $0.037BFY2025: $0.085B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 121.3%
52-week position88% through range
$8.12$17.42
News mentions794
Community mentions116partial coverage
U.S.-scope patents86
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal78/100
Management stability90/100
Market position3/100
Capital-event signal80/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2IRMD · Nasdaq

IRadimed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2004Winter Springs, Florida$1.11B market cap
View full Companies Radar profile
44Cautious
Snapshot price$87.07as of page date
Monthly-close return+157.7%five-year window
FY2025 revenue$0.08BIRADIMED CORP
Net margin26.8%FY2025
P/E snapshot48.6xone ratio, not a verdict
Prism attention13.7%share across these five
Filing track recordRevenue, USD billions
+100.4%
$0$0.0B$0.1B$0.1BFY2021: $0.042BFY2022: $0.053BFY2023: $0.066BFY2024: $0.073BFY2025: $0.084B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 19.0%
52-week position48% through range
$67.84$107.9
News mentions388
Community mentions0partial coverage
U.S.-scope patents52
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal77/100
Management stability90/100
Market position10/100
Capital-event signal15/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3LUNG · Nasdaq

Pulmonx

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1998Redwood City, California$100.5M market cap
View full Companies Radar profile
41Cautious
Snapshot price$2.38as of page date
Monthly-close return-94.0%five-year window
FY2025 revenue$0.09BPulmonx Corp
Net margin-59.7%FY2025
P/E snapshot-2.5xone ratio, not a verdict
Prism attention11.9%share across these five
Filing track recordRevenue, USD billions
+86.9%
$0$0.0B$0.1B$0.1BFY2021: $0.048BFY2022: $0.054BFY2023: $0.069BFY2024: $0.084BFY2025: $0.090B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.9%
52-week position71% through range
$1.13$2.89
News mentions338
Community mentions4partial coverage
U.S.-scope patents313
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability90/100
Market position0/100
Capital-event signal60/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4NPCE · Nasdaq

NeuroPace

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1997Mountain View, California$494.6M market cap
View full Companies Radar profile
40Cautious
Snapshot price$14.41as of page date
Monthly-close return-33.5%five-year window
FY2025 revenue$0.10BNeuroPace Inc
Net margin-21.5%FY2025
P/E snapshot-64.9xone ratio, not a verdict
Prism attention28.3%share across these five
Filing track recordRevenue, USD billions
+121.3%
$0$0.0B$0.1B$0.1BFY2021: $0.045BFY2022: $0.046BFY2023: $0.065BFY2024: $0.080BFY2025: $0.100B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.0%
52-week position52% through range
$8.88$19.60
News mentions804
Community mentions19partial coverage
U.S.-scope patents376
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal45/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5SGHT · Nasdaq

Sight Sciences

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2015Menlo Park, California$471.0M market cap
View full Companies Radar profile
37Cautious
Snapshot price$8.55as of page date
Monthly-close return-70.4%five-year window
FY2025 revenue$0.08BSight Sciences, Inc.
Net margin-49.7%FY2025
P/E snapshot-19.8xone ratio, not a verdict
Prism attention18.2%share across these five
Filing track recordRevenue, USD billions
+58.0%
$0$0.0B$0.1B$0.1BFY2021: $0.049BFY2022: $0.071BFY2023: $0.081BFY2024: $0.080BFY2025: $0.077B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.1%
52-week position89% through range
$3.19$9.24
News mentions518
Community mentions3partial coverage
U.S.-scope patents226
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position0/100
Capital-event signal58/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

IRadimed
+157.7%
Delcath
+63.9%
NeuroPace
-33.5%
Sight Sciences
-70.4%
Pulmonx
-94.0%

Latest revenue

USD billions, official filing scope shown on each company card.

NeuroPace
$0.10B
Pulmonx
$0.09B
Delcath
$0.09B
IRadimed
$0.08B
Sight Sciences
$0.08B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

IRadimed
26.8%
Delcath
3.2%
NeuroPace
-21.5%
Sight Sciences
-49.7%
Pulmonx
-59.7%

Prism news attention

Normalized share across these five names; attention is not quality.

NeuroPace
28.3%
Delcath
27.9%
Sight Sciences
18.2%
IRadimed
13.7%
Pulmonx
11.9%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

NeuroPace leads the conversation

It holds 28.3% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.10B.

Price path

IRadimed leads the available price paths

Its monthly-close return is +157.7% for the five-year window. At the other end, Pulmonx is -94.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

IRadimed has the widest latest margin

Its FY2025 net margin is 26.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

NeuroPace shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -64.9x while its five-year window price return is -33.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · NPCE

NeuroPace

804available Prism news records

Prism top themes

Earnings & financial performance
86
Price action & investor response
76
Macro demand & rates
13
Leadership & governance
5
Capital allocation & transactions
3

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+33.6%179 latest 12m vs 134 prior 12m
2024-01: 4 mentions2024-02: 5 mentions2024-03: 21 mentions2024-04: 8 mentions2024-05: 5 mentions2024-06: 1 mentions2024-07: 4 mentions2024-08: 9 mentions2024-09: 7 mentions2024-10: 9 mentions2024-11: 9 mentions2024-12: 12 mentions2025-01: 9 mentions2025-02: 23 mentions2025-03: 8 mentions2025-04: 12 mentions2025-05: 21 mentions2025-06: 11 mentions2025-07: 4 mentions2025-08: 8 mentions2025-09: 12 mentions2025-10: 21 mentions2025-11: 13 mentions2025-12: 12 mentions2026-01: 21 mentions2026-02: 12 mentions2026-03: 9 mentions2026-04: 50 mentions2026-05: 13 mentions2026-06: 4 mentions2024-012026-06

Machine-classified coverage tone

92.8% positive-1.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 20stock price 12responsive neurostimulation epilepsy 11earnings report 11epilepsy neuromodulation 9status epilepticus management 8seizure management 8stereoencephalography epilepsy 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-14–2026-06-04 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DCTH

Delcath

116 mentions
Stock and valuation
77
Products, pricing and logistics
10

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 116 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DCTH

Delcath

through 2026-02-26
Earnings releases 16Regulatory 7Leadership changes 6Board updates 2Asset acquisitions 1
  1. Earnings releases

    Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million , respectively

  2. Regulatory

    The options were granted on August 29, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to the terms and conditions of the Company’s 2023 Inducement Plan; the above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.

  3. Listing / IPO

    Delcath Systems Inc., of New York, said it closed its public offering of 15.3 million shares of common stock and warrants to purchase up to 4.6 million shares at a combined price of $1 .50 per share and related warrants. Gross proceeds of about $23 million will be used for general corporate purposes, including commercialization of the company's products, obtaining regulatory approvals, funding clinical trials and research and supporting capital expenditures and working capital.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IRMD

IRadimed

through 2026-02-10
Earnings releases 42M&A 5Listing / IPO 1
  1. Earnings releases

    We are thrilled to report our eighteenth consecutive quarter of record revenue, achieving $22.7 million in the fourth quarter of 2025—a 17% increase year-over-year and exceeding our previously announced guidance.

  2. M&A

    JPMorgan Chase & Co. boosted its stake in Iradimed by 70.2% during the third quarter.

  3. Listing / IPO

    Iradimed’s common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.”

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LUNG

Pulmonx

through 2025-11-13
Earnings releases 13Leadership changes 4
  1. Earnings releases

    contributing to a net loss of $14 million.

  2. Leadership changes

    Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the reappointment of Glen French as President and Chief Executive Officer, effective immediately, and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025.

  3. Leadership changes

    Steve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediately.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NPCE

NeuroPace

through 2026-03-22
Earnings releases 31Leadership changes 5
  1. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99 million 4.38 -$21.47 million ($0.66) -19.70 OPKO Health $606.90 million 1.40 -$225.68 million ($0.30) -3.73

  2. Leadership changes

    Ms. Kumar also serves as a director and as chair of the audit committee for NeuroPace (NASDAQ: NPCE), a medical device company dedicated to reducing debilitating seizures in patients with epilepsy.

  3. Earnings releases

    NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SGHT

Sight Sciences

through 2026-04-24
Earnings releases 26Leadership changes 11Company announcements 2
  1. Company announcements

    EYECARE Sight Sciences Issues 2025 Sustainability Report on ESG Initiatives

  2. Leadership changes

    Erica Rogers and Brenda Becker have stepped down from the Sight Sciences Board of Directors.

  3. Earnings releases

    On May 8, 2025, Sight Sciences reported its financial results for the first quarter of 2025, showing a 9% decrease in total revenue compared to the previous year, primarily due to reduced revenue from its Surgical Glaucoma segment.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence
2019 extracted base$10.20B–$11.75B
2025 extracted forecast$11.50B–$21.52B
Implied source CAGR7.4%
increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records
Latest 12m volume+8.7%36648 vs 33721 records
Positive classified tone66.7%+5.2 pp vs prior four quarters
2024-01: 2,862 mentions2024-02: 2,508 mentions2024-03: 2,665 mentions2024-04: 2,848 mentions2024-05: 2,984 mentions2024-06: 2,155 mentions2024-07: 2,123 mentions2024-08: 2,108 mentions2024-09: 2,116 mentions2024-10: 2,483 mentions2024-11: 2,604 mentions2024-12: 2,045 mentions2025-01: 2,853 mentions2025-02: 5,160 mentions2025-03: 3,909 mentions2025-04: 3,553 mentions2025-05: 2,612 mentions2025-06: 1,780 mentions2025-07: 3,188 mentions2025-08: 7,906 mentions2025-09: 2,642 mentions2025-10: 2,462 mentions2025-11: 2,103 mentions2025-12: 2,450 mentions2026-01: 1,736 mentions2026-02: 4,268 mentions2026-03: 3,588 mentions2026-04: 4,213 mentions2026-05: 312 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates
7,802
medical drama series
7,076
cannabis legalization trends & economic impact
6,207
recreational marijuana usage
5,579
in-flight medical emergency protocols
4,688
medical marijuana laws & regulatory frameworks
3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 26–33. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

NeuroPace has the widest attention-readiness rank gap

It ranks #1 by measured news attention (28.3%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open NeuroPace in Companies Radar

Pulmonx shows a price-operating divergence to inspect

Its displayed filing-revenue change is +86.9% while its available monthly-close return is -94.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Pulmonx in Companies Radar
Explanations

Attention measures coverage volume, not quality

NeuroPace's 28.3% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open NeuroPace in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Delcath's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 54/100 score.

Open Delcath in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon